A Randomized Control Trial to Investigate the Effectiveness of Smart Mental Health Interventions for Stress Reduction(inMind) During the Pharmacological Treatment in Mild to Moderate Major Depressive Disorder.

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study is a single-blind, multicenter, randomized, controlled crossover trial. The App, developed in South Korea, is an application that provides integrated interventions for stress reduction for the general population. The App provides three contents based on MBSR, CBT, and relaxation sounds that are known to be effective in stress reduction (Meditation category, Cognitive approach, and Relaxation Sound, respectively). Participants (n = 215) recruited via medical practitioner referral will be randomized to App first group (fAPP) or a waitlist crossover group (dAPP). Inclusion criteria are age 19-65; diagnosed with mild to moderate major depressive disorders (Score of 7-24 on the Hamilton Rating Scale for Depression); Stable medication for 28 days prior to study participation. The study was conducted over eight weeks, the fAPP group used The App for the first four weeks and the dAPP group for the next four weeks, and during all study periods, the participants received usual pharmacological treatment. Primary outcome measures are the Depression Anxiety Stress Scale-21. The analysis will use mixed-model repeated measures.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Maximum Age: 65
Healthy Volunteers: f
View:

• Adults between the ages of 19 and 65;

• Diagnosed with mild to moderate major depressive disorders in an expert interview evaluation according to the DSM-IV diagnostic criteria (Score of 7-24 on the Hamilton Rating Scale for Depression \[HAM-D\]);

• Stable medication for 28 days prior to study participation;

• Informed consent and voluntary participation.

Locations
Other Locations
Republic of Korea
Department of Psychiatry, Korea University Guro Hospital
RECRUITING
Seoul
Contact Information
Primary
Junhyung Kim, MD, PhD
jhcabilover@gmail.com
10-9317-1776
Time Frame
Start Date: 2022-05-15
Estimated Completion Date: 2023-12-31
Participants
Target number of participants: 42
Treatments
Other: the App first group (fAPP)
Participants assigned to fAPP group will use the App initially for 28 consecutive days (T1). After T1, during the next 28 consecutive days (T2) without washout period, fAPP will only maintain the usual treatment.
Other: wait list crossover group (dAPP)
During T1, participants assigned to the dAPP arm will maintain the usual treatment. After T1, during the next 28 consecutive days (T2) without washout period, dAPP will use the APP.
Related Therapeutic Areas
Sponsors
Collaborators: Ministry of Trade, Industry & Energy, Republic of Korea
Leads: Korea University Guro Hospital

This content was sourced from clinicaltrials.gov